Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback